Comparative Pharmacology
Head-to-head clinical analysis: EFUDEX versus INGENOL MEBUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFUDEX versus INGENOL MEBUTATE.
EFUDEX vs INGENOL MEBUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, leading to depletion of thymidine triphosphate and disruption of DNA synthesis. It is incorporated into RNA as a false metabolite, interfering with RNA processing and function.
Ingenol mebutate is a macrocyclic diterpene ester that induces rapid, mitochondria-dependent cell death (necrosis) in dysplastic keratinocytes upon topical application. It also activates protein kinase C (PKC) isoforms, specifically PKCδ, leading to mitochondrial dysfunction and release of pro-apoptotic factors. Additionally, it stimulates a local immune response via neutrophil-mediated oxidative burst and antibody-dependent cellular cytotoxicity.
For actinic keratosis: Apply topically to lesions twice daily for 2-4 weeks. For superficial basal cell carcinoma: Apply 5% cream twice daily for 3-6 weeks. Not for systemic use.
0.05% gel applied topically to the lesion once daily for 2 consecutive days per treatment course; repeat after 3 weeks if needed.
None Documented
None Documented
Terminal half-life is approximately 16 minutes (range 8-20 min) for parent drug; clinical context: due to rapid metabolism, continuous infusion or frequent dosing is required for sustained antimetabolite effect.
Terminal half-life approximately 18–24 hours; supports twice-daily application for actinic keratosis treatment.
Primarily hepatic metabolism to inactive metabolites; <15% excreted unchanged in urine; biliary/fecal excretion accounts for ~15%.
Primarily hepatobiliary excretion into feces; minimal renal elimination (<1% unchanged).
Category C
Category C
Topical Antineoplastic
Topical Antineoplastic